Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer – diagnostic difficulties Case report

Main Article Content

Kamila Skwierawska
Krzysztof Woźniak
Anna Waszczuk-Gajda
Joanna Drozd-Sokołowska
Piotr Kacprzyk
Marita Rachid Chehab
Piotr Boguradzki
Wiesław Wiktor Jędrzejczak
Grzegorz Władysław Basak


 Cancer-related microangiopathic hemolytic anemia is rarely recognized as a paraneoplastic syndrome with a very poor prognosis in cancer patients. The treatment and prognosis are significantly different from that in other thrombotic microangiopathies, such as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. The case of described patient demonstrates the diagnostic difficulties in diagnosing the causes of hemolytic anemia in patient with breast cancer and appropriate treatment.


Download data is not yet available.


Metrics Loading ...

Article Details

How to Cite
Skwierawska K, Woźniak K, Waszczuk-Gajda A, Drozd-Sokołowska J, Kacprzyk P, Chehab MR, Boguradzki P, Jędrzejczak WW, Basak GW. Cancer-related microagiopathic hemolytic anemia in a patient with breast cancer – diagnostic difficulties. OncoReview [Internet]. 2020Dec.31 [cited 2021Aug.1];10(4(40):134-8. Available from:


1. Lechner K, Obermeier HL. Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases. Medicine (Baltimore). 2012; 91(4): 195-205.
2. Takabatake D, Oishi K. Microangiopathic hemolytic anemia associated with metastatic breast cancer: case report and literature review. Springerplus. 2016; 5(1): 684.
3. Regierer AC, Kuehnhardt D, Schulz C et al. Breast Cancer-Associated Thrombotic Microangiopathy. Breast Care. 2011; 6: 441-5.
4. Hausberg M, Felten H, Pfeffer S. Treatment of Chemotherapy-Induced Thrombotic Microangiopathy with Eculizumab in a Patient with Metastatic Breast Cancer. Case Rep Oncol. 2019; 12: 1-6.
5. Lee EH, Otoukesh S, Abdi A et al. Hemolytic Anemia of Malignancy: A Case Study Involving Signet Ring Cell Metastatic Breast Cancer with Severe Microangiopathic Hemolytic Anemia. Case Rep Oncol. 2019; 12: 104-8.
6. Lara K, Bae E, Park H et al. A rare case of concurrent signet-ring carcinoma of breast and microangiopathic hemolytic anemia. J Surg Case Rep. 2016; (9): rjw132.
7. Morton JM, George JN. Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer. J Oncol Pract. 2016; 12(6): 523-30.
8. Babu KG, Bhat GR. Cancer-associated thrombotic microangiopathy. Ecancermedicalscience. 2016; 10: 649.
9. Chalasani P, Segar JM, Marron M et al: Pathophysiology of tumour-induced microangiopathic haemolytic anaemia. BMJ Case Rep. 2016; 2016.
10. Werner TL, Agarwal N, Carney HM et al. Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol. 2007; 82(4): 295-8.
11. Lindstrom LS, Karlsson E, Wilking UM et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012; 30: 2601-8.
12. Meng X, Song S, Jiang ZF et al. Receptor conversion in metastatic breast cancer: a prognosticator of survival. Oncotarget. 2016; 7(44): 71887-903.